Post by
piduks on Jun 13, 2024 2:58pm
Senior managements knows how to shoot off their mouth
but doesn't follow through with a public press release with tangible facts indicating what 2 drugs were approved by Brazil, what will they be used for, what is the current market revenue size for those 2 indications as well a targeted commercialization or launch date for investors to read.
The same holds true when senior management shoots their mouth off regarding launch of generic Epidiolex in the U.S. but fails to quantify tangible facts as to timing and if any of these drugs, including Brazil, are being done independently by Medipharm or with a NAMED partner in a press release.
I've been hiding too long in the shadows keeping quiet but listening very carefully to what management says and yet see no press releases to keep shareholders informed publicly.
It is time to get rid of the existing management and put in new managment that can clearly and effectively communicate to their shareholders because senior management will BRAG that they have a large time lead with their designations over any potential competitor but yet cannot effectively communicate tangible facts while the stock price under existing management has done NOTHING but languish under 10 cents for the last 2 years.
They will also talk about new B2B relationships but yet FAIL to issue a press release on those new relationships that will drive not only earnings but also the stock price because investors are forward looking when making investment decisions.